Page 3 - Solid Biosciences News Today

(RTTNews) - Solid Biosciences Inc. (SLDB) on Tuesday, announced that the FDA has granted Orphan Drug Designation (ODD) for its next-generation Duc...

/PRNewswire/ -- DelveInsights AAV Vectors in Gene Therapy Market Insights report includes a comprehensive understanding of current treatment practices,...

Solid Biosciences Inc. (NASDAQ:SLDB – Get Free Report) CFO Kevin Tan sold 3,935 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $8.20, for a total value of $32,267.00. Following the sale, the chief financial officer now directly owns 9,308 shares in the […]

Solid Biosciences Inc. entered into a securities purchase agreement with certain institutional accredited investors to issue common stock and Pre-Funded warrants for a aggregate proceeds of...

/PRNewswire/ -- Significant breakthroughs in the rapid and cost-effective analysis of the human genome have brought clarity to the path of discovering the...

Solid Biosciences Inc. (NASDAQ:SLDB – Get Free Report) COO David T. Howton sold 5,367 shares of Solid Biosciences stock in a transaction on Monday, December 4th. The stock was sold at an average price of $2.78, for a total value of $14,920.26. Following the sale, the chief operating officer now owns 7,684 shares in the […]

By Dean Seal Shares of Solid Biosciences rose after the company said regulators have granted their fast-track designation to its treatment for Duchenne muscular dystrophy. The stock was up...

Life sciences company Solid Biosciences Inc. (SLDB) announced Thursday that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SGT-003, the company's next-generation Duchenne muscular dystrophy gene therapy candidate.

Solid Biosciences Inc. (NASDAQ:SLDB – Get Free Report) insider Jessie Hanrahan sold 4,879 shares of Solid Biosciences stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $2.78, for a total value of $13,563.62. Following the transaction, the insider now owns 6,983 shares of the company’s […]

-- Solid Biosciences said Thursday that the US Food and Drug Administration has granted fast track designation to SGT-003, the companys Duchenne muscular dystrophy gene therapy candidate. The...